Thursday, June 01, 2017 9:41:17 AM
AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer
Ampliphi Biosciences Corp. (AMEX:APHB)
Intraday Stock Chart
Today : Thursday 1 June 2017
Click Here for more Ampliphi Biosciences Corp. Charts.
AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces the appointment of Paul C. Grint, M.D. as Chief Executive Officer, effective immediately. Dr. Grint has served on the Company’s board of directors since November 2015 and has more than two decades of executive leadership experience in biologics and small molecule development, including the successful development and commercialization of anti-infective products. M. Scott Salka has resigned as CEO and director of AmpliPhi, and will serve as a consultant to the Company during a transition period.
Dr. Grint previously served as President and CEO of Regulus Therapeutics Inc., a publicly traded biopharmaceutical company focused on the discovery and development of microRNA therapeutics. Prior to Regulus, he was President of Cerexa, Inc., where he was involved with the development of a portfolio of antibiotics for multidrug-resistant infections including ceftaroline and ceftazidime/avibactam combination. He previously served in senior management roles at Forest Research Institute, Kalypsys, Inc., Pfizer Inc., IDEC Pharmaceuticals Corporation and Schering-Plough Corporation. Dr. Grint is a director of the private biotechnology companies Amplyx Pharmaceuticals, Inc. and Synedgen, Inc. He received his bachelor’s degree from St. Mary’s Hospital in London and his medical degree from St. Bartholomew’s Hospital Medical College at the University of London. He is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and the author or co-author of more than 50 scientific publications.
“The board is delighted that Paul has agreed to take on the role of Chief Executive Officer at this critical time. His extensive experience in product development, clinical trials, drug approvals and anti-infectives will serve AmpliPhi well as our focus transitions to clinical development of phage therapies for patients with serious or life-threatening infections,” said Jeremy Curnock Cook, Chairman of AmpliPhi Biosciences. “The past 12 months have been transformative for AmpliPhi as our bacteriophage therapies have progressed through Phase 1 clinical trials. We have also shown the power of our phage-based approach to treat a critically ill patient with a multidrug-resistant (MDR) infection who faced death, being unresponsive to any commercially available antibiotic. On behalf of the board, I’d like to thank Scott for his many positive contributions to AmpliPhi over the past two years and wish him every success in his future endeavors.”
Commenting on his new position, Dr. Grint said, “My passion for innovative science and commercializing therapies that make a difference drew me to AmpliPhi Biosciences as a director, and I am thrilled to be assuming executive leadership of this exciting company. Our phage technology is much-needed in today’s world of antibiotic resistance which, if left unchecked, is projected to result in significant loss of life. AmpliPhi has the opportunity to be a meaningful player in addressing this looming public health crisis.”
About Antibiotic Resistance
Decades of misuse and over-use of antibiotics has led to the rise of multidrug-resistant and pan-resistant bacteria, commonly known as “superbugs.” These superbugs threaten to render existing antibiotic therapies useless, potentially thrusting the world into a “post-antibiotic” era where common infections may be life threatening. Hospitals regularly expose vulnerable patients to pathogenic bacteria. According to the World Health Organization, each year hundreds of millions of patients worldwide suffer from infections acquired in a hospital setting. The Centers for Disease Control and Prevention estimates that drug-resistant bacteria cause at least 2 million infections per year in the U.S. alone, resulting in over 23,000 deaths and many more people die from other conditions that are complicated by antibiotic-resistant infections. The 2016 O’Neill Report commissioned by the UK government projects that the failure to respond to the threat of antibiotic resistance and the rise of superbugs could lead to an estimated 10 million deaths per year from antibiotic-resistant infections worldwide by 2050, with an accumulated global cost of $100 trillion and a 3.5% reduction in global GDP.
Recent ARMP News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 11:50:05 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 08:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 09:00:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:20:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:15:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:09:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:25:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:15:50 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/04/2024 10:35:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:03:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/23/2024 09:17:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:55:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:55:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:54:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:54:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:54:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:53:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:53:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 02:53:27 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/15/2023 10:24:56 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM